Renal transplantation in the amyloidosis of familial Mediterranean fever. Experience in ten cases
- 1 October 1979
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 139 (10) , 1135-1138
- https://doi.org/10.1001/archinte.139.10.1135
Abstract
Ten patients with familial Mediterranean fever (FMF) and histologically confirmed amyloidosis received cadaver kidney transplants for treatment of terminal renal disease. Colchicine, 1 mg daily, was included in the routine postoperative regimen from 1974 for amyloidotic patients. Graft and patient survival were compared with 10 nonamyloidotic recipients of renal grafts matched for age, sex, type of allograft and HLA compatibility. In the FMF group, 5 of 10 grafts survived 20-64 mo.; in the control group, 6 of 10. While only recipients with functioning grafts survived in the FMF group, patient survival in the control group is 8 of 10 after 1 yr. In all 5 FMF survivors, graft function is satisfactory, proteinuria is absent and blood creatinine levels are normal. Amyloid involvement of an allograft was documented 16 mo. after transplantation in the only patient whose maintenance colchicine dosage was reduced to 0.5 mg daily.This publication has 4 references indexed in Scilit:
- Amyloidosis in a Renal Allograft in Familial Mediterranean FeverAnnals of Internal Medicine, 1977
- TRANSPLANTATION FOR RENAL AMYLOIDOSISTransplantation, 1977
- Amyloid Deposition in a Renal Transplant in Familial Mediterranean FeverAnnals of Internal Medicine, 1977
- Prophylactic Colchicine Therapy in Familial Mediterranean FeverAnnals of Internal Medicine, 1974